The entry of affordable Empagliflozin is expected to revolutionise diabetes management in India. Leading drugmakers like Mankind Pharma, Torrent, Alkem, Dr Reddy’s, and Lupin are expected to introduce generics within days. Currently priced at Rs 60 per tablet, the generic versions will be available for as low as Rs 9-Rs 14 per tablet. The diabetes drug market in India has grown from Rs 14,000 crore in 2021 to nearly Rs 20,000crore. With 10.1 crore Indians living with diabetes, according to the International Diabetes Federation, access to effective and affordable medication is critical. The move comes after the expiry of Boehringer Ingelheim’s patent on March 11, making way for affordable alternatives to the widely used diabetes drug, as per a Times of India report. to be launched within days, it has been learnt that Mankind Pharma plans to price its version at one-tenth of the innovator’s price.